AtriCure Change In Working Capital from 2010 to 2026
| ATRC Stock | USD 29.54 -0.32 -1.07% |
Change In Working Capital | First Reported 2004-09-30 | Previous Quarter 8.9 M | Current Value 137 K | Quarterly Volatility 5.5 M |
Macro event markers
Financial statement trends for AtriCure provide structured context on operating performance and capital structure. This context pairs drivers like Interest Expense of 6.2 M, Total Revenue of 561.3 M or Gross Profit of 417.6 M and ratios such as Price To Sales Ratio of 3.36, Dividend Yield of 0.0 or PTB Ratio of 3.69 with AtriCure Valuation and Volatility views.
AtriCure | Change In Working Capital | Build AI portfolio with AtriCure Stock |
Analyzing AtriCure's Change In Working Capital over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Change In Working Capital has evolved provides context for assessing AtriCure's current valuation and future prospects.
Latest AtriCure's Change In Working Capital Growth Pattern
Below is the plot of the Change In Working Capital of AtriCure over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. AtriCure's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AtriCure's overall financial position and show how it may be relating to other accounts over time.
| Change In Working Capital | 10 Years Trend |
|
Change In Working Capital |
| Timeline |
AtriCure Change In Working Capital Regression Statistics
| Arithmetic Mean | -5,597,849 | |
| Coefficient Of Variation | -125.10 | |
| Mean Deviation | 5,313,618 | |
| Median | -4,500,300 | |
| Standard Deviation | 7,002,905 | |
| Sample Variance | 49T | |
| Range | 21.5M | |
| R-Value | -0.57 | |
| Mean Square Error | 35.6T | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | -783,601 | |
| Total Sum of Squares | 784.7T |
AtriCure Change In Working Capital History
Stock Overview, Methodology & Data Sources
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Atricure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 875 people. As a mid-cap equity, AtriCure is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 33.47, P/B of 3.02, profit margin of -2.14%. AtriCure has a market cap of 1.47 B, P/E of 33.47, ROE of -2.4%.
Methodology
Unless otherwise specified, financial data for AtriCure is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. AtriCure (USA Stocks:ATRC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We reference public filings and market reference sources and regulatory disclosures, including those published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Data may be normalized and delayed in some cases. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
AtriCure may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for AtriCure Stock Analysis
Reviewing AtriCure commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for AtriCure Stock:AtriCure Correlation provides competitor comparison context for AtriCure. The view supports competitor context. Our How to Buy AtriCure Stock guide explains the steps to invest in AtriCure stock.Analysis related to AtriCure should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Earnings Share -0.24 | Revenue Per Share | Quarterly Revenue Growth 0.131 | Return On Assets | Return On Equity |
Investors evaluate AtriCure using market value and book value, each describing different facets of the business. AtriCure's market capitalization is 1.47 B. With a P/B ratio of 3.02, the market values AtriCure well above its book equity. Enterprise value stands at 1.39 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for AtriCure differs from its quoted price, since each reflects a different lens. For AtriCure, key inputs include a P/E ratio of 33.47, a P/B ratio of 3.02, a profit margin of -2.14%, and ROE of -2.4%. Trading price represents the transaction level agreed by market participants.